Drug profile · INN
canakinumab
CANAKINUMAB NOVARTIS
canakinumab (CANAKINUMAB NOVARTIS) is a interleukin-1 beta inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — canakinumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 7
- Data quality
- 0.84
Quick answer
canakinumab (CANAKINUMAB NOVARTIS) is a interleukin-1 beta inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-1 beta inhibitor
Primary target: Interleukin-1 beta
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is canakinumab?
canakinumab (CANAKINUMAB NOVARTIS) is a interleukin-1 beta inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for canakinumab?
CANAKINUMAB NOVARTIS is a marketed brand name for canakinumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of canakinumab?
canakinumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.